PMC:7600245 / 32956-33998 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T129","span":{"begin":190,"end":195},"obj":"Body_part"},{"id":"T130","span":{"begin":401,"end":413},"obj":"Body_part"},{"id":"T131","span":{"begin":575,"end":580},"obj":"Body_part"}],"attributes":[{"id":"A129","pred":"fma_id","subj":"T129","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A130","pred":"fma_id","subj":"T130","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A131","pred":"fma_id","subj":"T131","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Darunavir/cobicistat is under clinical investigation for the treatment of SARS-CoV-2 infection. This is potentially attributed to darunavir ability to in vitro inhibit SARS-CoV-2 in Vero E6 cells, albeit at high concentrations (EC50 = 46.41 µM) [104]. Mechanistically, this could be because darunavir potentially inhibits 3CLpro and/or PLpro of SARS-CoV-2. The two enzymes are important for the viral glycoprotein processing. However, in another in vitro study, darunavir/cobicistat demonstrated no activity against SARS-CoV-2 at clinically relevant concentrations in Caco-2 cells [105]. Furthermore, the results from a randomized controlled trial in China showed that darunavir/cobicistat was not effective in treating COVID-19 patients [106]. Regardless, darunavir is being tried in about three trials in combination with cobicistat (NCT04252274; n = 30), ritonavir/hydroxychloroquine (NCT04435587; n = 80), ritonavir/oseltamivir, ritonavir/oseltamivir/hydroxychloroquine, or ritonavir/favipiravir/hydroxychloroquine (NCT04303299; n = 320)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T120","span":{"begin":74,"end":82},"obj":"Disease"},{"id":"T121","span":{"begin":85,"end":94},"obj":"Disease"},{"id":"T122","span":{"begin":168,"end":176},"obj":"Disease"},{"id":"T123","span":{"begin":345,"end":353},"obj":"Disease"},{"id":"T124","span":{"begin":516,"end":524},"obj":"Disease"},{"id":"T125","span":{"begin":720,"end":728},"obj":"Disease"}],"attributes":[{"id":"A120","pred":"mondo_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A123","pred":"mondo_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A124","pred":"mondo_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A125","pred":"mondo_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Darunavir/cobicistat is under clinical investigation for the treatment of SARS-CoV-2 infection. This is potentially attributed to darunavir ability to in vitro inhibit SARS-CoV-2 in Vero E6 cells, albeit at high concentrations (EC50 = 46.41 µM) [104]. Mechanistically, this could be because darunavir potentially inhibits 3CLpro and/or PLpro of SARS-CoV-2. The two enzymes are important for the viral glycoprotein processing. However, in another in vitro study, darunavir/cobicistat demonstrated no activity against SARS-CoV-2 at clinically relevant concentrations in Caco-2 cells [105]. Furthermore, the results from a randomized controlled trial in China showed that darunavir/cobicistat was not effective in treating COVID-19 patients [106]. Regardless, darunavir is being tried in about three trials in combination with cobicistat (NCT04252274; n = 30), ritonavir/hydroxychloroquine (NCT04435587; n = 80), ritonavir/oseltamivir, ritonavir/oseltamivir/hydroxychloroquine, or ritonavir/favipiravir/hydroxychloroquine (NCT04303299; n = 320)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T298","span":{"begin":182,"end":195},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T299","span":{"begin":499,"end":507},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T300","span":{"begin":568,"end":574},"obj":"http://purl.obolibrary.org/obo/CLO_0002172"},{"id":"T301","span":{"begin":568,"end":574},"obj":"http://purl.obolibrary.org/obo/CLO_0051943"},{"id":"T302","span":{"begin":568,"end":574},"obj":"http://purl.obolibrary.org/obo/CLO_0051958"},{"id":"T303","span":{"begin":568,"end":574},"obj":"http://purl.obolibrary.org/obo/CLO_0051960"},{"id":"T304","span":{"begin":575,"end":580},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T305","span":{"begin":618,"end":619},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Darunavir/cobicistat is under clinical investigation for the treatment of SARS-CoV-2 infection. This is potentially attributed to darunavir ability to in vitro inhibit SARS-CoV-2 in Vero E6 cells, albeit at high concentrations (EC50 = 46.41 µM) [104]. Mechanistically, this could be because darunavir potentially inhibits 3CLpro and/or PLpro of SARS-CoV-2. The two enzymes are important for the viral glycoprotein processing. However, in another in vitro study, darunavir/cobicistat demonstrated no activity against SARS-CoV-2 at clinically relevant concentrations in Caco-2 cells [105]. Furthermore, the results from a randomized controlled trial in China showed that darunavir/cobicistat was not effective in treating COVID-19 patients [106]. Regardless, darunavir is being tried in about three trials in combination with cobicistat (NCT04252274; n = 30), ritonavir/hydroxychloroquine (NCT04435587; n = 80), ritonavir/oseltamivir, ritonavir/oseltamivir/hydroxychloroquine, or ritonavir/favipiravir/hydroxychloroquine (NCT04303299; n = 320)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T491","span":{"begin":0,"end":9},"obj":"Chemical"},{"id":"T492","span":{"begin":10,"end":20},"obj":"Chemical"},{"id":"T493","span":{"begin":130,"end":139},"obj":"Chemical"},{"id":"T494","span":{"begin":291,"end":300},"obj":"Chemical"},{"id":"T495","span":{"begin":401,"end":413},"obj":"Chemical"},{"id":"T496","span":{"begin":462,"end":471},"obj":"Chemical"},{"id":"T497","span":{"begin":472,"end":482},"obj":"Chemical"},{"id":"T498","span":{"begin":669,"end":678},"obj":"Chemical"},{"id":"T499","span":{"begin":679,"end":689},"obj":"Chemical"},{"id":"T500","span":{"begin":757,"end":766},"obj":"Chemical"},{"id":"T501","span":{"begin":824,"end":834},"obj":"Chemical"},{"id":"T502","span":{"begin":858,"end":867},"obj":"Chemical"},{"id":"T503","span":{"begin":868,"end":886},"obj":"Chemical"},{"id":"T504","span":{"begin":910,"end":919},"obj":"Chemical"},{"id":"T505","span":{"begin":920,"end":931},"obj":"Chemical"},{"id":"T506","span":{"begin":933,"end":942},"obj":"Chemical"},{"id":"T507","span":{"begin":943,"end":954},"obj":"Chemical"},{"id":"T508","span":{"begin":955,"end":973},"obj":"Chemical"},{"id":"T509","span":{"begin":978,"end":987},"obj":"Chemical"},{"id":"T510","span":{"begin":988,"end":999},"obj":"Chemical"},{"id":"T511","span":{"begin":1000,"end":1018},"obj":"Chemical"}],"attributes":[{"id":"A491","pred":"chebi_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A492","pred":"chebi_id","subj":"T492","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A493","pred":"chebi_id","subj":"T493","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A494","pred":"chebi_id","subj":"T494","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A495","pred":"chebi_id","subj":"T495","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A496","pred":"chebi_id","subj":"T496","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A497","pred":"chebi_id","subj":"T497","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A498","pred":"chebi_id","subj":"T498","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A499","pred":"chebi_id","subj":"T499","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A500","pred":"chebi_id","subj":"T500","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A501","pred":"chebi_id","subj":"T501","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A502","pred":"chebi_id","subj":"T502","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A503","pred":"chebi_id","subj":"T503","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A504","pred":"chebi_id","subj":"T504","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A505","pred":"chebi_id","subj":"T505","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A506","pred":"chebi_id","subj":"T506","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A507","pred":"chebi_id","subj":"T507","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A508","pred":"chebi_id","subj":"T508","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A509","pred":"chebi_id","subj":"T509","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A510","pred":"chebi_id","subj":"T510","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A511","pred":"chebi_id","subj":"T511","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"Darunavir/cobicistat is under clinical investigation for the treatment of SARS-CoV-2 infection. This is potentially attributed to darunavir ability to in vitro inhibit SARS-CoV-2 in Vero E6 cells, albeit at high concentrations (EC50 = 46.41 µM) [104]. Mechanistically, this could be because darunavir potentially inhibits 3CLpro and/or PLpro of SARS-CoV-2. The two enzymes are important for the viral glycoprotein processing. However, in another in vitro study, darunavir/cobicistat demonstrated no activity against SARS-CoV-2 at clinically relevant concentrations in Caco-2 cells [105]. Furthermore, the results from a randomized controlled trial in China showed that darunavir/cobicistat was not effective in treating COVID-19 patients [106]. Regardless, darunavir is being tried in about three trials in combination with cobicistat (NCT04252274; n = 30), ritonavir/hydroxychloroquine (NCT04435587; n = 80), ritonavir/oseltamivir, ritonavir/oseltamivir/hydroxychloroquine, or ritonavir/favipiravir/hydroxychloroquine (NCT04303299; n = 320)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T240","span":{"begin":0,"end":95},"obj":"Sentence"},{"id":"T241","span":{"begin":96,"end":251},"obj":"Sentence"},{"id":"T242","span":{"begin":252,"end":356},"obj":"Sentence"},{"id":"T243","span":{"begin":357,"end":425},"obj":"Sentence"},{"id":"T244","span":{"begin":426,"end":587},"obj":"Sentence"},{"id":"T245","span":{"begin":588,"end":744},"obj":"Sentence"},{"id":"T246","span":{"begin":745,"end":1042},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Darunavir/cobicistat is under clinical investigation for the treatment of SARS-CoV-2 infection. This is potentially attributed to darunavir ability to in vitro inhibit SARS-CoV-2 in Vero E6 cells, albeit at high concentrations (EC50 = 46.41 µM) [104]. Mechanistically, this could be because darunavir potentially inhibits 3CLpro and/or PLpro of SARS-CoV-2. The two enzymes are important for the viral glycoprotein processing. However, in another in vitro study, darunavir/cobicistat demonstrated no activity against SARS-CoV-2 at clinically relevant concentrations in Caco-2 cells [105]. Furthermore, the results from a randomized controlled trial in China showed that darunavir/cobicistat was not effective in treating COVID-19 patients [106]. Regardless, darunavir is being tried in about three trials in combination with cobicistat (NCT04252274; n = 30), ritonavir/hydroxychloroquine (NCT04435587; n = 80), ritonavir/oseltamivir, ritonavir/oseltamivir/hydroxychloroquine, or ritonavir/favipiravir/hydroxychloroquine (NCT04303299; n = 320)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"965","span":{"begin":336,"end":341},"obj":"Gene"},{"id":"966","span":{"begin":168,"end":178},"obj":"Species"},{"id":"967","span":{"begin":345,"end":355},"obj":"Species"},{"id":"968","span":{"begin":516,"end":526},"obj":"Species"},{"id":"969","span":{"begin":729,"end":737},"obj":"Species"},{"id":"970","span":{"begin":0,"end":20},"obj":"Chemical"},{"id":"971","span":{"begin":130,"end":139},"obj":"Chemical"},{"id":"972","span":{"begin":291,"end":300},"obj":"Chemical"},{"id":"973","span":{"begin":462,"end":472},"obj":"Chemical"},{"id":"974","span":{"begin":472,"end":482},"obj":"Chemical"},{"id":"975","span":{"begin":669,"end":689},"obj":"Chemical"},{"id":"976","span":{"begin":757,"end":766},"obj":"Chemical"},{"id":"977","span":{"begin":824,"end":834},"obj":"Chemical"},{"id":"978","span":{"begin":858,"end":886},"obj":"Chemical"},{"id":"979","span":{"begin":910,"end":931},"obj":"Chemical"},{"id":"980","span":{"begin":933,"end":942},"obj":"Chemical"},{"id":"981","span":{"begin":943,"end":954},"obj":"Chemical"},{"id":"982","span":{"begin":955,"end":973},"obj":"Chemical"},{"id":"983","span":{"begin":978,"end":1018},"obj":"Chemical"},{"id":"984","span":{"begin":74,"end":94},"obj":"Disease"},{"id":"985","span":{"begin":720,"end":728},"obj":"Disease"},{"id":"986","span":{"begin":187,"end":189},"obj":"CellLine"},{"id":"987","span":{"begin":568,"end":574},"obj":"CellLine"}],"attributes":[{"id":"A965","pred":"tao:has_database_id","subj":"965","obj":"Gene:43740578"},{"id":"A966","pred":"tao:has_database_id","subj":"966","obj":"Tax:2697049"},{"id":"A967","pred":"tao:has_database_id","subj":"967","obj":"Tax:2697049"},{"id":"A968","pred":"tao:has_database_id","subj":"968","obj":"Tax:2697049"},{"id":"A969","pred":"tao:has_database_id","subj":"969","obj":"Tax:9606"},{"id":"A971","pred":"tao:has_database_id","subj":"971","obj":"MESH:D000069454"},{"id":"A972","pred":"tao:has_database_id","subj":"972","obj":"MESH:D000069454"},{"id":"A973","pred":"tao:has_database_id","subj":"973","obj":"MESH:D000069454"},{"id":"A974","pred":"tao:has_database_id","subj":"974","obj":"MESH:D000069547"},{"id":"A976","pred":"tao:has_database_id","subj":"976","obj":"MESH:D000069454"},{"id":"A977","pred":"tao:has_database_id","subj":"977","obj":"MESH:D000069547"},{"id":"A980","pred":"tao:has_database_id","subj":"980","obj":"MESH:D019438"},{"id":"A981","pred":"tao:has_database_id","subj":"981","obj":"MESH:D053139"},{"id":"A982","pred":"tao:has_database_id","subj":"982","obj":"MESH:D006886"},{"id":"A984","pred":"tao:has_database_id","subj":"984","obj":"MESH:C000657245"},{"id":"A985","pred":"tao:has_database_id","subj":"985","obj":"MESH:C000657245"},{"id":"A986","pred":"tao:has_database_id","subj":"986","obj":"CVCL:4582"},{"id":"A987","pred":"tao:has_database_id","subj":"987","obj":"CVCL:0025"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Darunavir/cobicistat is under clinical investigation for the treatment of SARS-CoV-2 infection. This is potentially attributed to darunavir ability to in vitro inhibit SARS-CoV-2 in Vero E6 cells, albeit at high concentrations (EC50 = 46.41 µM) [104]. Mechanistically, this could be because darunavir potentially inhibits 3CLpro and/or PLpro of SARS-CoV-2. The two enzymes are important for the viral glycoprotein processing. However, in another in vitro study, darunavir/cobicistat demonstrated no activity against SARS-CoV-2 at clinically relevant concentrations in Caco-2 cells [105]. Furthermore, the results from a randomized controlled trial in China showed that darunavir/cobicistat was not effective in treating COVID-19 patients [106]. Regardless, darunavir is being tried in about three trials in combination with cobicistat (NCT04252274; n = 30), ritonavir/hydroxychloroquine (NCT04435587; n = 80), ritonavir/oseltamivir, ritonavir/oseltamivir/hydroxychloroquine, or ritonavir/favipiravir/hydroxychloroquine (NCT04303299; n = 320)."}